

COMEQ

SOLUTION

For Veterinary Use Only

COMPOSITION:

Each ml contains:

Flumequine200mg

Colistin Sulphate25,000IU

PHARMACOLOGY

Cyclic polypeptide antibiotic from *Bacillus colistinus*. It is composed of Polymyxin E1 and E2 (or Colistin sulphate A, B, and C) which act as detergents on cell membranes. Colistin sulphate is less toxic than Polymyxin B, but otherwise similar; the methane sulfonate is used orally. Colistin sulphate is a polymyxin antibiotic agent. Polymyxin are cationic polypeptides that disrupt the bacterial cell membrane through a detergent like mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporin's, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, and the lack of new antimicrobial agents have led to the revived use of the polymyxins. Flumequine is considered to be well absorbed and is excreted in the urine and feces as the glucuronide conjugates of the parent drug and 7-hydroxyflumequine. It is eliminated within 168 hours post-dosing. The major residue found in the edible tissues of sheep, pigs, and chickens was parent drug together with minor amounts of the 7-hydroxy-metabolite.

INDICATION:

Comeq Solution is indicated for the treatment of infectious diseases caused by microorganisms susceptible to Flumequine and Colistin, such as bacterial diarrhea, enteritis, urinary tract infections, mastitis, pneumonia and multiple arthritis.

TOXICOLOGY

Toxicity (Overdose): Oral LD50 in rats is 5450 mg/kg. Over dosage with Colistin can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death. No protein binding or biotransformation was available. Flumequine was associated with severe ocular toxicity; Drug-induced calculi (kidney stones) has been associated with such therapy as well. Anaphylactic shock induced by Flumequine therapy has also been associated with its use. Anaphylactic reactions such as shock, urticarial, and

Quince's edema have been reported to generally appear within two hours photo toxicity resulting in skin reactions like erythema, pruritus, urticarial and severe rashes, gastrointestinal and neurological disorders.

DOSAGE AND ADMINISTRATION

Administer via drinking water;

Treatment: 1ml in 2 liters for 3-5 days

Prevention: 1ml in 4 liters for 3-5 days

PRECAUTIONS

- Shake well before use
- Withdrawal time
 - Eggs : 4 days
 - Meat : 4 days
- Store between 15-25°C in a cool and dry place.
- Consult the Veterinarian before use
- Keep out of the reach of children.

Innovator's Specs



 **Selmores**
Pharmaceuticals (Pvt) Ltd.

Manufactured by:
Selmores Pharmaceuticals (Pvt) Ltd.
36 Km Multan Road, Lahore, Pakistan.

